Claims data show higher mortality risk than other drug types for pain
Source: Long-Acting Opioids Carry Higher Risk of Death | Medpage Today
Claims data show higher mortality risk than other drug types for pain
Source: Long-Acting Opioids Carry Higher Risk of Death | Medpage Today
Last August, Canadian police seized 110 illegal fentanyl pills at a home in Alberta province. Yesterday, Global News reported that some of the pills have tested positive for an extremely potent opi…
Source: W-18, a synthetic opiate 100 times more potent than fentanyl | The Poison Review
The analyses showed alcohol was involved in 18.5% of OPR and 27.2% of benzodiazepine drug abuse-related ED visits and 22.1% of OPR and 21.4% of benzodiazepine drug-related deaths. These findings indicate that alcohol plays a significant role in OPR and benzodiazepine abuse. Interventions to reduce the abuse of alcohol and these drugs alone and in combination are needed.
JAMA Network | JAMA | Treating Prescription Opioid Dependence.
Conclusions and Relevance This study represents a rigorous experimental evaluation of outpatient buprenorphine stabilization, brief taper, and naltrexone maintenance for treatment of PO dependence. Results suggest that a meaningful subset of PO-dependent outpatients may respond positively to a 4-week
Naltrexone maintenance? I bet they’ll lost weight too.
Deaths From Narcotic Painkillers Quadrupled in Past Decade: CDC – WebMD.
Deaths from overdoses of drugs such as hydrocodone (Vicodin), morphine and oxycodone (Oxycontin) climbed from 1.4 per 100,000 people to 5.4 per 100,000, according to the U.S. Centers for Disease Control and Prevention.
That means about 3,000 people died in 1999 from unintentional overdoses. By 2011, that number was up to nearly 12,000 deaths, the report said.
If you read the source article you’ll never look at constipation the same way ever again. Better dig deeper to find out why your applicant is constipated. It may not be just a horrible diet and lack of dietary fiber.
And yet another FDA approved drug to counteract adverse effects from another FDA approved drug.
FDA Okays Naloxegol Movantik in Opioid-Induced Constipation.
The US Food and Drug Administration (FDA) has approved naloxegol (Movantik, AstraZeneca Pharmaceuticals), a peripherally acting opioid receptor antagonist, for the treatment of opioid-induced constipation (OIC) in adults with chronic noncancer pain.
OIC is a common adverse effect of opioid use. An estimated 40% to 80% of patients receiving long-term opioid therapy experience OIC, which can be severe enough to cause discontinuation of opioid therapy.